Comparative efficacy and safety of first-line therapies for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
BACKGROUND First-line regimens incorporating immune checkpoint inhibitors (ICIs), adoptive cell therapy (ACT), and targeted agents have expanded treatment options for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma, but their comparative efficacy and safety remain uncertain. METHODS We sear...